Open AccessMDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Author(s) -
Anna E. Vilgelm,
Nabil Saleh,
Rebecca L. Shattuck-Brandt,
Kelsie Riemenschneider,
Lauren Slesur,
SheauChiann Chen,
Christopher Andrew Johnson,
Jinming Yang,
Ashlyn Blevins,
Chi Yan,
Douglas B. Johnson,
Rami N. AlRohil,
Ensar Halilovic,
Rondi M. Kauffmann,
Mark C. Kelley,
Gregory D. Ayers,
Ann Richmond
Publication year - 2019
Publication title -
science translational medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.aav7171
Subject(s) - antagonism , mdm2 , pharmacology , cancer research , medicine , chemistry , biology , receptor , cell culture , genetics
CDK4/6 inhibition becomes effective in preclinical models of melanoma when combined with MDM2 antagonism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom